On March 31, 2022 Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, reported that company management will participate in the following upcoming investor conferences (Press release, Arrakis Therapeutics, MAR 31, 2022, View Source [SID1234611317]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare
Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m. ET in New York. Company management will also participate in one-on-one meetings.

21st Annual Needham Virtual Healthcare Conference
Company management will participate in one-on-one meetings on Tuesday, April 12, 2022.